Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
- Feb 19, 2021 (filed on Feb 19, 2021)Insider Name:Exter NeilOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:Form 3/A : Amendment of a previous Form 3# or value acquired/disposed of:--Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Series D Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-1,737,619Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Series C Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-3,125,000Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Series A Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-7,119,850Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:150,000Price:$18.00
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:C - Conversion# or value acquired/disposed of:327,852Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:C - Conversion# or value acquired/disposed of:247,324Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:C - Conversion# or value acquired/disposed of:458,487Price:--
- Feb 17, 2021 (filed on Feb 18, 2021)Insider Name:Longevity Fund 2 LPOwnership Type:Direct OwnershipSecurities:Convertible Series C Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-79,143Price:--
- Feb 17, 2021 (filed on Feb 18, 2021)Insider Name:Longevity Fund 2 LPOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:C - Conversion# or value acquired/disposed of:79,143Price:--
Filings by filing date
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Series D Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-1,737,619Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Series C Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-3,125,000Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Series A Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-7,119,850Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:150,000Price:$18.00
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:C - Conversion# or value acquired/disposed of:327,852Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:C - Conversion# or value acquired/disposed of:247,324Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Glaxosmithkline PlcOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:C - Conversion# or value acquired/disposed of:458,487Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Orbimed Advisors LlcOwnership Type:Indirect OwnershipSecurities:Series D Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-1,158,412Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Orbimed Advisors LlcOwnership Type:Indirect OwnershipSecurities:Series D Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-1,737,619Price:--
- Feb 17, 2021 (filed on Feb 19, 2021)Insider Name:Orbimed Advisors LlcOwnership Type:Indirect OwnershipSecurities:Series D Preferred StockNature of Transaction:C - Conversion# or value acquired/disposed of:-14,480,162Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1325 Boylston Street, Suite 500 BOSTON MA 02215 |
Tel: | N/A |
Website: | https://www.decibeltx.com |
IR: | See website |
Key People | ||
Laurence E. Reid Chief Executive Officer, Director | Gabriel Corfas Founder | M. Charles Liberman Founder |
Ulrich Mueller Founder | Elisabeth Leiderman Chief Financial Officer |
Business Overview |
Decibel Therapeutics Inc is a clinical-stage biotechnology company. The Company is focused on discovering and developing transformative treatments for hearing and balance disorders. The Company is focused on restoring and improving hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. The Company has built a platform that integrates single-cell genomics and bioinformatics analyses, precision gene therapy technologies and its proficiency in inner ear biology. The Company's pipeline product includes its gene therapy program (DB-OTO) to treat congenital monogenic deafness and its ototoxicity prevention program. Its products pipeline also includes AAV.103, AAV.104, DB-ATO and AAV.201. |
Financial Overview |
For the nine months ended 30 September 2020, DecibelTherapeutics Inc revenues was not reported. Net lossapplicable to common stockholders decreased 22% to $34.7M.Lower net loss reflects R&D bal decrease of 44% to $14.4M(expense), General and administrative - Bal decrease of 27%to $8.1M (expense), Stock-based Compensation in R&Ddecrease of 15% to $352K (expense). |
Employees: | 37 as of Dec 31, 2020 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $489.19M as of Sep 30, 2020 |
Annual revenue (TTM): | $0.00M as of Sep 30, 2020 |
EBITDA (TTM): | -$27.67M as of Sep 30, 2020 |
Net annual income (TTM): | -$43.73M as of Sep 30, 2020 |
Free cash flow (TTM): | -$38.35M as of Sep 30, 2020 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 24,217,428 as of Feb 12, 2021 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |